Literature DB >> 25115683

Trends in prevalence and treatment of ocular allergy.

Paulo J Gomes1.   

Abstract

PURPOSE OF REVIEW: This review describes recent findings and trends in prevalence and treatment of allergic ocular diseases. Although the major focus is on seasonal and perennial allergic conjunctivitis, related disorders will also be considered. RECENT
FINDINGS: Published reports from countries around the world suggest that the spectrum of atopic diseases, including seasonal and perennial allergic conjunctivitis, is continuing its pattern of increasing prevalence, which has been well documented over the past few decades. In addition, although treatment modalities have focused on topical formulations including antihistamines and corticosteroids, there is a significant emphasis on immunotherapy as an alternative treatment modality, particularly in the USA.
SUMMARY: Allergic conjunctivitis is a key component in the spectrum of allergic diseases that is sometimes collectively referred to as rhinoconjunctivitis. Because of its high prevalence worldwide, it exacts an increasing toll in terms of patient discomfort, morbidity, and loss of productivity. Current estimates suggest that at least 20% of the overall population suffers from some form of allergic conjunctivitis, many without ever seeking treatments. In addition, a significant proportion of patients experience chronic forms of allergy that are less responsive to existing therapies. Recent approval of immunotherapy-based treatments may address this therapeutic gap.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115683     DOI: 10.1097/ACI.0000000000000100

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  15 in total

Review 1.  Mucosal immune tolerance at the ocular surface in health and disease.

Authors:  Jeremías G Galletti; Mauricio Guzmán; Mirta N Giordano
Journal:  Immunology       Date:  2017-02-20       Impact factor: 7.397

2.  Combination Therapy of 0.1% Fluorometholone and 0.05% Azelastine in Eyes with Severe Allergic Conjunctival Diseases: A Randomized Controlled Trial.

Authors:  Minjie Chen; Bilian Ke; Jun Zou; Lan Gong; Yan Wang; Chaoran Zhang; Jianjiang Xu; Anji Wei; Jiaxu Hong
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

Review 3.  Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management.

Authors:  Stacey Ackerman; Lisa M Smith; Paulo J Gomes
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

4.  Prevalence of allergic conjunctivitis among basic school children in the Kumasi Metropolis (Ghana): a community-based cross-sectional study.

Authors:  David Ben Kumah; Seth Yaw Lartey; Felix Yemanyi; Evans Gyimah Boateng; Emmanuel Awuah
Journal:  BMC Ophthalmol       Date:  2015-07-03       Impact factor: 2.209

5.  Effect of alcaftadine 0.25% on ocular itch associated with seasonal or perennial allergic conjunctivitis: a pooled analysis of two multicenter randomized clinical trials.

Authors:  Joseph B Ciolino; Eugene B McLaurin; Nicholas P Marsico; Stacey L Ackerman; Julia M Williams; Linda Villanueva; David A Hollander
Journal:  Clin Ophthalmol       Date:  2015-05-02

6.  Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model.

Authors:  Edward J Meier; Gail L Torkildsen; Paul J Gomes; Mark C Jasek
Journal:  Clin Ophthalmol       Date:  2018-12-13

7.  Lipoxin A4 Counter-regulates Histamine-stimulated Glycoconjugate Secretion in Conjunctival Goblet Cells.

Authors:  Robin R Hodges; Dayu Li; Marie A Shatos; Charles N Serhan; Darlene A Dartt
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

8.  Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief.

Authors:  Warner Carr; Jack Schaeffer; Eric Donnenfeld
Journal:  Allergy Rhinol (Providence)       Date:  2016-07-26

9.  The Prevalence of Ocular Allergy and Comorbidities in Chinese School Children in Shanghai.

Authors:  Yanqing Feng; Xiangning Wang; Fang Wang; Rongming Liu; Lu Chen; Shuqin Wu; Xia Yang; Miaoying Chen; Yu-Qing Rao; Jing Li
Journal:  Biomed Res Int       Date:  2017-08-21       Impact factor: 3.411

10.  Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies.

Authors:  Edward Meier; Abhijit Narvekar; Ganesh R Iyer; Harvey B DuBiner; Apinya Vutikullird; David Wirta; Kenneth Sall
Journal:  Clin Ophthalmol       Date:  2017-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.